Details for New Drug Application (NDA): 206586
✉ Email this page to a colleague
NDA 206586 describes BUPRENORPHINE HYDROCHLORIDE, which is a drug marketed by Alvogen, Am Regent, Endo Operations, Hikma, Hospira, Actavis Elizabeth, Barr, Ethypharm, Norvium Bioscience, Rhodes Pharms, Rubicon, Sun Pharm, Difgen Pharms, Dr Reddys Labs Sa, Mylan Technologies, Alkem Labs Ltd, Amneal Pharms, Ethypharm Usa Corp, Lannett Co Inc, Specgx Llc, Teva Pharms Usa, and Wes Pharma Inc, and is included in thirty-one NDAs. It is available from twenty suppliers. Additional details are available on the BUPRENORPHINE HYDROCHLORIDE profile page.
The generic ingredient in BUPRENORPHINE HYDROCHLORIDE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
The generic ingredient in BUPRENORPHINE HYDROCHLORIDE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 206586
| Tradename: | BUPRENORPHINE HYDROCHLORIDE |
| Applicant: | Endo Operations |
| Ingredient: | buprenorphine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 206586
| Mechanism of Action | Partial Opioid Agonists |
Suppliers and Packaging for NDA: 206586
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE | buprenorphine hydrochloride | INJECTABLE;INJECTION | 206586 | ANDA | ENDO USA, Inc. | 42023-179 | 42023-179-05 | 5 VIAL in 1 CARTON (42023-179-05) / 1 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 0.3MG BASE/ML | ||||
| Approval Date: | Jul 28, 2015 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
